Mode
Text Size
Log in / Sign up
N/A N=61 Treatment

A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)

Fecal Incontinence

Enrolled (actual)
61
Serious AEs
1.6%
Results posted
May 2015
Primary outcome: Primary: Frequency of FI Episodes — 79; 86 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
vaginal bowel control system (LivSure) (Device)
Age
Adult, Older Adult · 19+ yrs
Sex
Female
Sponsor
Pelvalon, Inc.
Primary completion
Jan 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Frequency of FI Episodes
79; 86
SECONDARY
Number of Incontinent Days
2.1; 11.6
SECONDARY
Device-related Adverse Events
18

Summary

The objective of this study is to obtain preliminary efficacy and safety data on the use of the LivSure System (now called the "Eclipse™ System") in women with fecal incontinence.

Eligibility Criteria

Inclusion Criteria

  • History of FI for at least 6 months
  • Baseline diary requirement for min # of FI episodes in a two-week period
  • Ability to manage investigational device insertion and removal
  • Successful fitting of study device
  • Willing and able to give written informed consent to participate in the study

Exclusion Criteria

  • Chronic rectal, anal or pelvic pain
  • Any vaginal prolapse that extends beyond the plane of the hymen.
  • Previous rectal or pelvic floor surgery within the last 12 months (24 months in the case of cancer)
  • Congenital anorectal malformation
  • Chronic watery diarrhea unmanageable by drugs or diet as primary cause of FI
  • Inflammatory bowel disease
  • Presence of a vaginal, anal, rectal or urethral fistula or anastomosis
  • Presence of a vaginal, rectal or bladder tumor
  • Presence of an open wound or tear in the vagina or anus by exam
  • Presence or history of rectovaginal fistula
  • Atrophic vaginal tissue as determined by symptoms or visualization
  • Current vaginal or urinary infection requiring treatment
  • History of recurrent urinary or vaginal infections
  • Subject is currently pregnant or planning pregnancy in next 5 months
  • Concurrent use of any intra-vaginal device that would interfere with LivSure (now called Eclipse) placement or wearing
  • Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.) or other factor that the investigator believes would interfere with study participation and/or increase subject risk
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01655498). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search